An experimental sod seeder

The design and development of an efficient sod‐seeder for the Ngongoni Veld of Natal is described.     

Effects of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor velagliflozin,a new drug with therapeutic potential to treat diabetes in cats

Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are used in the treatment of human diabetics. They increase glucose excretion and correct hyperglycemia. We examined the investigational SGLT2 inhibitor velagliflozin in two groups of six neutered adult obese cats (equal gender distribution). Placebo (Pl) or drug (D; 1 mg/kg) was administered for 35 days. Routine blood examinations, fructosamine, beta‐hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), glucagon, adiponectin, and leptin were measured before and after treatment, also water intake, and urinary electrolytes, glucose, and volume. Indirect calorimetry, an intravenous glucose tolerance test (IVGTT; 0.8 g/kg) and insulin tolerance test (IVITT) were conducted. All cats tolerated treatment well. Significant changes with D included a decrease in the respiratory exchange ratio, an increase in cholesterol, a small increase in albumin, and a rise in BHB and NEFA. Glucose clearance was unaltered, although less insulin was secreted during the IVGTT (p = .056) suggesting improved insulin sensitivity. IVITT was unchanged. Treatment did not affect glucagon, leptin, or adiponectin. Water intake, urine output, urinary glucose excretion, and the glucose/creatinine ratio but not urinary electrolytes were significantly higher post‐D. We conclude that velagliflozin is a promising drug, which increases urinary glucose excretion in cats and could thereby be beneficial for the treatment of hyperglycemia.     

Feline vaccine‐associated sarcomagenesis: Is there an inflammation‐independent role for aluminium?

Aluminium has been found in feline vaccine‐associated sarcomas. In this study, we investigated the potential for aluminium to contribute directly to tumourigenesis. Our results indicated that an aluminium hydroxide adjuvant preparation was cytotoxic and mutagenic in human‐Chinese hamster ovary (CHO) hybrid cells in vitro. Moreover, CHO cells deficient in DNA double strand break (DSB), but not single‐strand break (SSB), repair, were particularly sensitive to aluminium exposure compared with repair proficient cells, suggesting that aluminium is associated with DSBs. In contrast to CHO cells, primary feline skin fibroblasts were resistant to the cytotoxic effects of aluminium compounds and exposure to an aluminium chloride salt promoted cell growth and cell cycle progression at concentrations much less than those measured in particular feline rabies vaccines. These findings suggest that aluminium exposure may contribute, theoretically, to both initiation and promotion of tumours in the absence of an inflammatory response.     

Studies on the various sugar-urea and sugar-starch-urea relationships with reference to the fermentation in the rumen and the digestibility of nutrients in fattening cattle]

Recommendations are given saying that sugar-to-crude fibre rations of not more than 1.7:1 and sugar-to-urea ratios of 12:1 should be used in the fattening of cattle fed urea-supplemented rations of roughages in which 40% to 50% of the crude protein content of the ration had been replaced by urea. The amount of sugar per kg live-weight should not exceed 4 g. Higher quantities reduce the digestibility of crude fibre and, additionally, decrease the NH3 level and the pH in the rumen. At the same time the amount of volatile fatty acids is increased while the content of ruminal acetic acid decreases. Variations in the sugar-to-starch ratio had no statistically significant influence on the nitrogen balance whereas it was found that increasing quantities of sugar significantly decreased the digestibility of crude fibre. The proportional content of sugar in the readily metabolisable carbohydrates contained in the ration should not exceed 20% to 50%.     

Opto-electronic counters for postlarvae and juveniles of Machrobrachium rosenbergii (de Man); design and tests of Type A counter

Postlarvae or juveniles of Macrobrachium rosenbergii produced in Mauritius are sold at unit price to prawn farmers and are counted individually by hand. This process is time consuming, labour intensive, subject to error and may stress the juveniles; safe rapid electronic counting would be highly advantageous.The design of the hydraulic component of a successful counter prototype, Type A, is described. The counter has 10 parallel channels through which juveniles are carried in a water current. The detection of juveniles passing through these channels can be done photo-electrically. The counter accepts juveniles up to 15 mm in length (eye orbit to tip telson) and has the significant advantage that it can be constructed using only simple hand tools.Survival and growth rate tests, and microscopic examination for damage to appendages of juveniles were done on machine counted and hand counted juveniles. There was no reduction of growth or survival caused by passage through the counter by comparison with the hand counting method, and it is concluded that the counter is not detrimental to juvenile prawns.About 70% of all juveniles tested showed highly variable amounts of damage. The great majority of this damage appears to originate in the hatchery tanks, prior to the experimental treatments. Only in the case of antennules could the use of the counter be shown to increase damage significantly, i.e. from 25% to 38%, but this has no detectable effect on subsequent survival or growth.This appears to be the first counter made specifically for counting macroscopic crustacean juveniles, and via suitable scaling, adaptation to counting other species of crustaceans, fish larvae, etc., should be possible.     

Toxoplasmosis in two cats with inflammatory intestinal disease

Lymphocytic-plasmacytic enteritis, a chronic inflammatory intestinal disease, was diagnosed in 2 cats. In 1 cat, recurrence of clinical signs after initiating treatment was attributed to relapse of the inflammatory intestinal disease, but was found to be attributable to relapsing toxoplasmosis secondary to immunosuppressive drug therapy. Treatment with clindamycin resolved the recurrent toxoplasmosis. In the second cat, clinical signs of toxoplasmosis did not develop, but serologic testing yielded evidence of active toxoplasmosis. Treatment with clindamycin caused the titers to decrease. Relapsing toxoplasmosis may be responsible for apparent resistance to treatment in cats for inflammatory intestinal disease being treated with immunosuppressive drugs.     

In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance

The activities of danofloxacin, a novel fluoroquinolone, and two other antimicrobials were determined in vitro against field isolates of seven Mycoplasma species of veterinary importance isolated from cattle, swine and poultry in five European countries. The minimum inhibitory concentrations (MIC) of danofloxacin, tylosin and oxytetracycline were determined against a total of 68 isolates. Danofloxacin showed excellent activity against isolates of all Mycoplasma species (range 0·008 to 0·5 μg ml⁻¹), but in some isolates there was evidence of reduced sensitivity to tylosin (range 0·008 to 2·0 μg ml⁻¹) and oxytetracycline (range 0·008 to over 16·0 μg ml⁻¹). Danofloxacin was more active than other antimicrobials against, M hyopneumoniae, M dispar and M bovigenitalium, and showed activity similar to that of tylosin against M bovis and M gallisepticum. Tylosin was the most active against M synoviae and M hyosynoviae. Generally, oxytetracycline showed the poorest activity, but was superior to tylosin against M bovigenitalium. A second (final) MIC reading was taken for all isolates 14 or 21 days after the initial reading, and MIC values rose during that time. However, the increase seen in danofloxacin values (typically one to two dilutions) was less than that seen for tylosin and oxytetracycline. It is concluded that danofloxacin is highly active in vitro against all of the Mycoplasma species tested, and thus shows great potential for the treatment of respiratory and other infections caused by Mycoplasma species in cattle, pigs and poultry.